Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Kahn Swick & Foti, LLCSarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPTFormer Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT)...
- Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPRClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or the...
- Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS InsiderU.S. Atopic Dermatitis Drugs Market to Reach USD 8.62 Billion and Europe USD 7.87 Billion by 2035 as Biologic Therapy Expansion, JAK Inhibitor Adoption, and Novel Remission-Inducing Treatments Drive Demand.
- Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsenCompanies: NovartisRoyalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical congress.
- Defence Therapeutics Inc.Defence Therapeutics Provides Updates on Sharing AgreementDefence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 2026.On March 6, 2026, the Company completed a...
- Actinium Pharmaceuticals, Inc.Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and Chief Executive Officer, will present at the H.C. Wainwright...
- Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsMatinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. As of June 30, 2026, the Company had stockholders’ equity of $1.8 million and has had losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(ii) and Section 1003(a)(iii) of the Company Guide. Due to its noncompliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.
- Bright Minds BiosciencesBright Minds Biosciences to Present at Upcoming ConferencesBright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:
- ORIC PharmaceuticalsORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2026 (the “Grant Date”), ORIC granted a total of 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees who began their employment with ORIC in August 2026.
- Vera TherapeuticsVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- Intellia Therapeutics, Inc.Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.